In 1867 James Lane and George Gascoyen, surgeons to the London Lock Hospital, compiled a report on their experiments with a new and controversial treatment. The procedure, known as "syphilization," saw patients be inoculated with infective matter taken from a primary syphilitic ulcer or the artificial sores produced in another patient. Each patient received between 102 and 468 inoculations to determine whether syphilization could cure syphilis and produce immunity against reinfection. This article examines the theory and practice of this experimental treatment. Conducted against the backdrop of the Contagious Diseases Acts, the English syphilization experiments have been largely forgotten. Yet they constitute an important case study of how doctors thought about the etiology and pathology of syphilis, as well as their responsibilities to their patients, at a crucial moment before the advent of the bacteriological revolution.

Download full-text PDF

Source
http://dx.doi.org/10.1353/bhm.2017.0001DOI Listing

Publication Analysis

Top Keywords

london lock
8
lock hospital
8
syphilization discontents
4
discontents experimental
4
experimental inoculation
4
inoculation syphilis
4
syphilis london
4
hospital 1867
4
1867 james
4
james lane
4

Similar Publications

Left atrial myxoma metastasizing to the brain: a case report and review of literature.

Radiat Oncol J

December 2024

London Health Sciences Centre, Schulich School of Medicine, Western University, London, ON, Canada.

Cardiac myxomas, the most common primary cardiac tumors, are believed to originate from multipotent mesenchymal cells. Approximately 75% of myxomas occur within the left atrium, increasing the risk of systemic thromboembolic events. While typically benign, atrial myxomas can rarely metastasize to the brain, with fewer than 60 cases reported.

View Article and Find Full Text PDF

CD73, an ectoenzyme responsible for adenosine production, is often elevated in immuno-suppressive tumor environments. Inhibition of CD73 activity holds great promise as a therapeutic strategy for CD73-expressing cancers. In this study, we have developed a therapeutic anti-human CD73 antibody cocktail, HB0045.

View Article and Find Full Text PDF

Background: Elinzanetant is a dual neurokinin-1,3 receptor antagonist in development for the treatment of menopausal vasomotor symptoms. The objectives of these studies were to characterize the mass balance and biotransformation of elinzanetant.

Methods: In the clinical evaluation, whole blood, plasma, urine, and feces were collected from healthy fasted male volunteers (n = 6) following a single dose of 120 mg [C]-elinzanetant oral suspension for analysis of total radioactivity and metabolite profiling.

View Article and Find Full Text PDF

Importance: Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.

Objective: To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.

Design, Setting, And Participants: This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!